San Diego, CA, United States of America

Kathryn Susan Prickett

This inventor holds 38 USPTO granted patents and 1 published patent application, plus 2 CIPO patents and 8 EPO patents, primarily in Peptide Therapeutics. Top assignees: Amylin Pharmaceuticals, Inc., Astrazeneca Pharmaceuticals LP, Other. Active years: 1996-2014.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kathryn Susan Prickett. Retrieved from https://idiyas.com/inventor/kathryn-susan-prickett

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 38 

% Patents Active = 28.9


 

Average Co-Inventor Count = 3.0

ph-index = 26

Forward Citations = 1,849(Granted Patents)


Location History:

  • San Francisco, CA (US) (2010)
  • Hillsborough, CA (US) (2010)
  • San Diego, CA (US) (1996 - 2013)
  • Foster City, CA (US) (2011 - 2014)

Company Filing History:


Years Active: 1996-2014

Loading Chart...
Loading Chart...
Loading Chart...
Areas of Expertise:
Exendin Agonists
Amylin Peptides
Peptide Therapeutics
Diabetes Treatment
GLP-1 Agonists
Polycystic Ovary Syndrome
Gestational Diabetes
Appetite Regulation
Pharmaceutical Compositions
Gastrointestinal Motility
Inotropic Effects
Diuretic Effects
38 patents (USPTO):Explore Patents

Title: The Innovative Journey of Kathryn Susan Prickett

Introduction

Kathryn Susan Prickett, based in San Diego, California, is a prolific inventor with 38 patents to her name. Her groundbreaking work in the medical field, particularly related to peptides and treatment methods, has significantly contributed to advancements in healthcare.

Latest Patents

Among her most recent patents, Kathryn has innovated in the realm of pancreatic polypeptide family motifs. Her invention provides novel Pancreatic Polypeptide Family (PPF) polypeptides and methods for their application. Additionally, Kathryn has developed methods that increase urine flow through the administration of GLP-1 or exendin peptides. These methods are pivotal for treating a variety of conditions associated with toxic hypervolemia, including renal failure and congestive heart failure. Furthermore, her research delves into pharmaceutical compositions that aid in inducing an inotropic response, enhancing cardiac contractility in patients with specific disorders.

Career Highlights

Kathryn has had an impressive career with noteworthy positions at Amylin Pharmaceuticals, Inc. and AstraZeneca Pharmaceuticals LP. Her tenure at these companies has enabled her to hone her skills in drug development and innovation in medicinal therapies.

Collaborations

Throughout her career, Kathryn has collaborated with esteemed colleagues such as Andrew A Young and Nigel Robert Arnold Beeley. These partnerships have furthered her research efforts and led to substantial contributions to the biomedical field.

Conclusion

In summary, Kathryn Susan Prickett's contributions to the field of medicine through her innovative patents and collaborations have paved the way for new treatments and methodologies. Her ongoing commitment to research and development continues to inspire future innovations.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…